胃癌为全球第四大常见肿瘤,其病死率高,居肿瘤死亡原因第2位,全球每年约有934000新发病例,其中死亡近700000例〔1〕。尽管外科手术技巧不断提高,临床诊断水平在不断进步,新的化学治疗药物也在不断发展,但是临床结果显示进展期胃癌以及胃食管交界癌症患者5年生存率仍只有5%～15%。分子靶向药物治疗的进展为胃癌治疗开辟了新的途径。 Gastric cancer is the fourth most common tumor in the world, with a high case fatality rate and the second leading cause of cancer deaths. There are about 934,000 new cases of global cancer each year, of which nearly 700,000 cases of death [1]. In spite of rising surgical skills and clinical diagnosis, new chemotherapeutic drugs are evolving. However, clinical results show that the 5-year survival rate of patients with advanced gastric cancer and gastroesophageal junction cancer is still only 5% -15%. The progress of molecular targeted drug therapy has opened up a new way for the treatment of gastric cancer.